Navigation Links
Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
Date:9/19/2013

SAN DIEGO, Sept. 19, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the BioCentury NewsMakers in the Biotech Industry conference at the Millennium Broadway Hotel in New York City on Friday, September 27, 2013.

Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug candidate, quizartinib, at 8:30 a.m. EDT.  The presentation will be webcast live through the "Investors & Media" section of the Ambit website at www.ambitbio.com.  An audio replay will be available for 30 days following the initial presentation webcast. 

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.Ambit Contacts:Marcy Graham

Ian Stone/
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
2. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
3. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
4. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
5. Ambit Biosciences to Present at Two Upcoming Investor Conferences
6. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
7. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
8. Natural Skin Care Solution, Probiotic Action Announces the Use of Their Probiotic Cleanser As a Anti-Acne Body Wash
9. Creabilis Announces Treatment of First Patients in its Phase 2b Trial of CT327 in Pruritus in Atopic Dermatitis Patients
10. Neogen announces 1st quarter results conference call
11. Global Industry Analysts, Inc. Announces the Launch of a Major Research Program Analysing the Global Market for Circulating Tumor Cells and Cancer Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 2014 RURO, Inc., a leading ... released Limfinity® version 5.1.4. , RURO’s deployment teams ... than ever in RURO’s 8 year history. Many ... enhancement. Limfinity® version 5.1.4 is the perfect example ... bug fixes! , Limfinity® 5.1.4 release highlights – ...
(Date:11/22/2014)... 2014   , ... Officer zu KLOX    ... Financial Officer bestellt    KLOX ist ... jüngst zugelassenen Behandlungssystems zur Wundheilung zu beginnen    , ... ist sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
(Date:11/21/2014)... Author Matthew J. Pallamary’s second short story ... published as a tribute to his mentor Ray ... Story” category of the 2014 USA Best Book ... USA Book News, said this year’s contest yielded over ... & Schuster, Penguin, John Wiley & Sons, Houghton Mifflin ...
(Date:11/21/2014)... 2014 Why did Stephen Hawking become ... so instantly recognizable? Why have they become icons to ... author Hilton Ratcliffe seeks out the answers to those ... to do with science. In " Stephen Hawking Smoked ... 21, 2014), Ratcliffe puts it plainly: , “It ...
Breaking Biology Technology:RURO Announces Limfinity® version 5.1.4 2KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4
... that want the benefits of cutting-edge health care possibilities ... sub-populations need to foster the new science at ... by Nature Publishing Group. , In a special six-paper ... (NRG), researchers from the McLaughlin-Rotman Centre for Global Health ...
... a significant milestone for the growing open source clincial trials ... towards the needs of regulated industry sponsored clinical trials. ... ... 2008 -- Akaza Research announces the availability of OpenClinica 2.5, ...
... ABBOTT PARK, Ill., Sept. 19 Abbott (NYSE:,ABT) will ... 2008, before the market opens., The announcement will ... call at 8 a.m. Central time (9 a.m. Eastern), ... at, http://www.abbottinvestor.com . An archived edition of the call ...
Cached Biology Technology:As personalized, genomic medicine takes off, four developing countries show the way for others 2As personalized, genomic medicine takes off, four developing countries show the way for others 3As personalized, genomic medicine takes off, four developing countries show the way for others 4As personalized, genomic medicine takes off, four developing countries show the way for others 5As personalized, genomic medicine takes off, four developing countries show the way for others 6As personalized, genomic medicine takes off, four developing countries show the way for others 7Akaza Research Releases New Version of OpenClinica Electronic Data Capture (EDC) Software; Targets Industry Clinical Trials 2Akaza Research Releases New Version of OpenClinica Electronic Data Capture (EDC) Software; Targets Industry Clinical Trials 3
(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)...  The Secure Identity & Biometrics Association (SIBA) ... the formation of The Airport Entry and Exit ... and Biometric Entry and Exit Solutions Framework for ... from BORDERPOL, the international non-profit organization that works ... regarding border security, traveler and migration systems. ...
(Date:11/18/2014)... , Nov. 17, 2014 The Parenteral Drug ... U.S. regulatory agencies will speak and at least seven more ... Conference at the Omni Shoreham Hotel in Washington ... once again to have significant support from the regulatory agencies ... Europe in our effort to help advance ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... Virginia Key, FL March 14, 2011 -- The University ... proud to announce that Dr. Peter Mumby is the 2011 ... honors. Mumby, a British marine ecologist and professor at Australia,s ... Award. His goal is to understand the benefits and limitations ...
... common parasitic infection can vary greatly from person to person, ... three strains of the cat-borne parasite Toxoplasma gondii ... invades. Past research suggests that the parasite, estimated to ... psychotic symptoms and schizophrenia in genetically predisposed people. The ...
... premier plant biology journals published by the American Society of ... The Plant Cell -- completed their migration to HighWire ... HighWire, the online hosting platform for more than 1,000 scholarly ... a standards-based hosting solution that is putting ASPB,s journals at ...
Cached Biology News:Peter Mumby to receive prestigious 2011 Rosenstiel Award from the University of Miami 2Toxoplasmosis: The strain explains severity of infection 2ASPB journals migrate to new Web platform 2
... channels for automated gigaseal patch clamping. ... voltage-gated ion channels, such as hERG and ... The four pipette heads afford more efficient ... drug discovery. The glass-coated tunnels of ...
... plating in just seconds , No ... flaming, More uniform spreading and more colonies, ... bottle for spreading 100 plates or single-use tubes ... way to spread cells on multiple plates simultaneously ...
... culture or fermentation is the ability to ... make rapid adjustments in response to changes ... provide immediate analysis of key nutrients, metabolites, ... media. BioProfile analyzers are fully automated, multi-test ...
... acid synthetic peptide whose sequence is from rat SCAMP 5. ... C - N(217) - Q - P - Q - T ... P - N - Y - T - Y - S ... and control experiments with the polyclonal antibody that reacts with this ...
Biology Products: